Acepodia, Inc. (TPEX:6976)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
23.50
-0.30 (-1.26%)
Feb 21, 2025, 1:49 PM CST
-19.93%
Market Cap 13.39B
Revenue (ttm) 16.90M
Net Income (ttm) -379.78M
Shares Out 569.64M
EPS (ttm) -0.54
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,276,564
Average Volume 1,120,668
Open 23.80
Previous Close 23.80
Day's Range 22.95 - 23.80
52-Week Range 17.00 - 32.00
Beta n/a
RSI 76.70
Earnings Date Mar 26, 2025

About Acepodia

Acepodia, Inc. operates as a clinical stage biotechnology company. The company engages in developing cell therapies with its antibody cell conjugation (ACC) platform technology to address cancer care. It links tumor targeting antibodies to its proprietary immune cells, such as gamma delta 2 T cells to create novel ACE therapies. In addition, the company develops ACE 1831 targeting CD20 that is in phase 1 clinical trial; ACE 2016 targeting EGFR, which is in preclinical study; ACE1708; and ACE1702 targeting HER2 that is in phase 1 clinical trial.... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Shih-Chia Hsiao
Country Cayman Islands
Stock Exchange Taipei Exchange
Ticker Symbol 6976
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.